Pharmaceutical company Cipla Limited (BSE:500087) (NSE:CIPLA EQ) reported on Monday the receipt of the final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3ml from the US Food and Drug Administration (FDA).
According to the company, the Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
The Icatibant Injectable pre-filled syringe in 30mg/3ml is an AP-rated generic version of Shire's Firazyr.
For the 12-month period ending May 2020, Firazyr and its generic equivalents had US sales of approximately USD270m based on data from IQVIA (IMS Health).
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules